Children reading picture books together on the floor—scholarship as a shared, gentle habit
Photo: Kyle Hinkson / Unsplash

Peer-reviewed literature

Key clinical and pharmacometric publications on inpegsomatropin (Pegpesen®): Phase II PK/PD, Phase III efficacy, and population modeling for dosing strategies.

Google Scholar direction · PubMed verified

Updated literature check

Literature discovery was checked around the product name, generic name, and title-level phrases used in Google Scholar-style searches. The references shown here are linked through PubMed, DOI, publisher, or local PDF copies so the page does not depend on unstable search-result snippets.

PMID 39607675 · 2025

A Novel Y-Shaped Pegylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency.

Pivotal multicenter randomized Phase III evidence in pediatric GHD, published in The Journal of Clinical Endocrinology & Metabolism.

PubMed
PMID 41191222 · 2026

Optimization of dosing regimens for the long-acting growth hormone pegpesen.

Population PK/PD modeling paper in Journal of Endocrinological Investigation, published online in 2025 and indexed as a 2026 article.

PubMed
PMID 36034448 · 2022

PK/PD properties and short-term outcome of once-weekly PEGylated rhGH.

Phase II randomized multicenter study in pediatric GHD, published in Frontiers in Endocrinology.

PubMed

Phase II — PK, PD & 12-week growth

Liang Y, Zhang C, Wei H, Du H, Zhang G, Yang Y, Zhang H, Gong H, Li P, Song F, Xu Z, He R, Zhou W, Zheng H, Sun L, Luo X. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency. Front Endocrinol (Lausanne). 2022;13:922304.

DOI: 10.3389/fendo.2022.922304 · NCT04513171

Open Phase II topic Download PDF

Featured topic: Population PK/PD dosing optimization — summarized tables, timelines, limitations, and a bundled PDF of the Journal of Endocrinological Investigation (2026) modeling paper.

Population PK / PD (dosing science)

Zhao Y, Zou F, Gu J, He R, Yin Y. Optimization of dosing regimens for the long-acting growth hormone pegpesen: A population PK/PD modeling approach. J Endocrinol Invest (2026) 49:599–607. Online 5 Nov 2025.

DOI: 10.1007/s40618-025-02749-4

Open topic page Download PDF

Pediatric GHD Phase III (efficacy & safety)

Liang Y, Wei H, Yang F, Zhang H, Chen L, Yao H, Luo X, Cheng X, Yang Y, Lian Q, Du H, Li T, Li P, Zhang G, Song F, Liang L, Liu D, Zhu S, Gong H, Gong C, Cheng X, Xu Z, Ma Y, Su Z, Zhou W, He R, Yin Y, Sun L, Luo X. A Novel Y-Shaped Pegylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency. The Journal of Clinical Endocrinology & Metabolism. 2024; advance access 28 November 2024.

DOI: 10.1210/clinem/dgae816

Download PDF (local copy) Publisher page

The PDF in docs/phase3-jcem-2024.pdf mirrors the long-filename original in the project root; update both if you replace the file.